With more than 100,000 people currently waiting for a life-saving transplant, expanding the donor pool is an imperative. Dr. Christine Durand and our TRC team lead HOPE in Action, a multi-site NIH-funded trial, bringing HOPE to every community and studying the long-term safety and feasibility of HIV-HIV organ donation and transplantation.

Alcohol-associated liver disease (ALD) is the leading indication for liver transplants in the US. Historically, most centers required patients to abstain from alcohol for six months before their liver transplants, and many with severe ALD could not receive transplants in time. The NIH/NIAAA-funded DELTA Center for Alcohol Research is home to interdisciplinary bench, clinical, and population health research studies dedicated to enhancing the delivery of early liver transplants to persons with severe ALD. Our team of experts is committed to developing evidence-based practices and care protocols for ALD that transplant centers can implement worldwide.

COVID-19 Antibody Testing of Recipients of Solid Organ Transplants is being led by the transplant team at Johns Hopkins. The study has been approved by the Johns Hopkins Institutional Review Board (IRB00248540). The purpose of this research study is to determine COVID-19 antibody levels in transplant recipients who get the COVID-19 vaccine.

Expanding the donor pool through the use of organs from donors with hepatitis C virus for recipients without hepatitis C (HCV D+/R-) has become more common in recent years due to the discovery of an effective cure for hepatitis C. The PREVENT HCV study, a multi-site NIH-funded randomized controlled trial, aims to find out which is better in HCV D+/R- kidney transplants: taking a shorter course of the HCV medication that starts prior to transplant, or taking a full course of treatment that starts after treatment.